Efficacy and predictors of short-term first-generation somatostatin analog presurgical treatment in acromegaly: A hospital-based study of 237 cases

被引：11

作者：

Shen, Ming ^{[1
,3
,5
,6
,7
]}

Yang, Yeping ^{[2
]}

He, Wenqiang ^{[1
,3
,5
,6
,7
]}

Qiao, Nidan ^{[1
,3
,5
,6
,7
]}

He, Min ^{[2
,3
]}

Shou, Xuefei ^{[1
,3
,5
,6
,7
]}

Wang, Meng ^{[2
]}

Ma, Zengyi ^{[1
,3
,5
,6
,7
]}

Ye, Zhao ^{[1
,3
,5
,6
,7
]}

Zhang, Yichao ^{[1
,3
,5
,6
,7
]}

Chen, Zhengyuan ^{[1
,3
,5
,6
,7
]}

Zhang, Qilin ^{[1
,3
,5
,6
,7
]}

Zhou, Xiang ^{[1
,3
,5
,6
,7
]}

Cao, Xiaoyun ^{[1
,3
,5
,6
,7
]}

Ye, Hongying ^{[2
,3
]}

Wang, Yongfei ^{[1
,3
,5
,6
,7
]}

Li, Shiqi ^{[1
,3
,5
,6
,7
]}

Li, Yiming ^{[2
,3
]}

Zhao, Yao ^{[1
,3
,4
,5
,6
,7
]}

Zhang, Zhaoyun ^{[2
,3
,4
]}

机构：

[1] Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai 200040, Peoples R China

[2] Fudan Univ, Huashan Hosp, Dept Endocrinol & Metab, Shanghai 200040, Peoples R China

[3] Shanghai Pituitary Tumor Ctr, Shanghai 200040, Peoples R China

[4] Fudan Univ, Huashan Hosp, Natl Clin Res Ctr Aging & Med, Shanghai 200040, Peoples R China

[5] Fudan Univ, Neurosurg Inst, Shanghai 200040, Peoples R China

[6] Shanghai Clin Med Ctr Neurosurg, Shanghai 200040, Peoples R China

[7] Shanghai Key Lab Brain Funct & Restorat & Neural, Shanghai 200040, Peoples R China

来源：

GROWTH HORMONE & IGF RESEARCH | 2020年 / 55卷

基金：

中国国家自然科学基金;

关键词：

Acromegaly; Growth hormone-secreting pituitary adenoma; Presurgical treatment; Somatostatin analogs; Granulation pattern; PREOPERATIVE OCTREOTIDE TREATMENT; SECRETING PITUITARY-ADENOMAS; GROWTH-HORMONE; CLINICOPATHOLOGICAL FEATURES; TUMOR VOLUME; THERAPY; PATTERN; RATES;

D O I：

10.1016/j.ghir.2020.101354

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Objective: To investigate the effectiveness and predictors of short-term somatostatin analog (SSA) presurgical therapy in a large cohort and to assess the correlation between clinical and pathological variables. Design: 237 newly diagnosed patients with acromegaly received presurgical SSA treatment for three months were recruited. Clinical characteristics were collected, and response to SSA in hormone and tumor size was evaluated. The correlation between clinical information and pathological variables were analyzed. Results: After 3 months presurgical SSA therapy, 51 (21.5%) patients were biochemically responsive with 2 cm and age 2 cm, patients with MTD 49 years than <= 49 years (48.1% and 31.0% P = 0.089). Conclusions: The baseline MTD and age correlate with granulation patterns and may be used as easily acquired predictors of presurgical SSA treatment in acromegaly. Patients over their 50s with a tumor less than 2 cm in diameter are more likely to have a response to the short-term presurgical SSA therapy.

引用

页数：6

共 28 条

[1] Pre-surgical medical treatment, a major prognostic factor for long-term remission in acromegaly
Albarel, F.
Castinetti, F.
Morange, I.
Guibert, N.
Graillon, T.
Dufour, H.
Brue, T.
[J]. PITUITARY, 2018, 21 (06) : 615 - 623
[2] Relationship between cytokeratin staining patterns and clinico-pathological features in somatotropinomae
Bakhtiar, Yuriz
Hirano, Hirofumi
Arita, Kazunori
Yunoue, Shunji
Fujio, Shingo
Tominaga, Atsushi
Sakoguchi, Tetsuhiko
Sugiyama, Kazuhiko
Kurisu, Kaoru
Yasufuku-Takano, Junko
Takano, Koji
[J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2010, 163 (04) : 531 - 539
[3] Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls
Biermasz, NR
van Dulken, H
Roelfsema, F
[J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (10) : 3551 - 3555
[4] Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience
Brzana, Jessica
Yedinak, Chris G.
Gultekin, Sakir H.
Delashaw, Johnny B.
Fleseriu, Maria
[J]. PITUITARY, 2013, 16 (04) : 490 - 498
[5] Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: A prospective, randomized trial
Carlsen, Sven M.
Lund-Johansen, Morten
Schreiner, Thomas
Aanderud, Sylvi
Johannesen, Oivind
Svartberg, Johan
Cooper, John G.
Hald, John K.
Fougner, Stine L.
Bollerslev, Jens
[J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (08) : 2984 - 2990
[6] Acromegaly Clinical Trial Methodology Impact on Reported Biochemical Efficacy Rates of Somatostatin Receptor Ligand Treatments: A Meta-Analysis
Carmichael, John D.
Bonert, Vivien S.
Nuno, Miriam
Ly, Diana
Melmed, Shlomo
[J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (05) : 1825 - 1833
[7] Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial
Caron, Philippe J.
Bevan, John S.
Petersenn, Stephan
Flanagan, Daniel
Tabarin, Antoine
Prevost, Gaetan
Maisonobe, Pascal
Clermont, Antoine
[J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (04) : 1282 - 1290
[8] Acromegaly
Colao, Annamaria
Grasso, Ludovica F. S.
Giustina, Andrea
Melmed, Shlomo
Chanson, Philippe
Pereira, Alberto M.
Pivonello, Rosario
[J]. NATURE REVIEWS DISEASE PRIMERS, 2019, 5 (1)
[9] Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Colao, Annamaria
Auriemma, Renata S.
Pivonello, Rosario
Kasuki, Leandro
Gadelha, Monica R.
[J]. PITUITARY, 2016, 19 (03) : 235 - 247
[10] The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
Colao, Annamaria
Auriemma, Renata S.
Pivonello, Rosario
[J]. PITUITARY, 2016, 19 (02) : 210 - 221

← 1 2 3 →